¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
¿µ¹® gene therapy ÇÑ±Û À¯ÀüÀÚ¿ä¹ý
¼³¸í   
  À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇϴ ´ÜÀÏÀ¯ÀüÀڠȤÀº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼­ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇϴ °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇϴ ġ·á·Î¼­ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °­ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ È¯ÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇϴ ¸ñÀûÀ¸·Î ¾²ÀδÙ.
¿µ¹® Electric convulsive therapy(ECT) ÇÑ±Û Àü±â°æ·Ã¿ä¹ý
¼³¸í   
  ³ú¿¡ Àü±â ÀÚ±ØÀ» ÁÖ¾î ÀÎÀ§ÀûÀ¸·Î °æ·ÃÀ» À¯¹ßÇÔÀ¸·Î½á Á¤½Å º´À» Ä¡·áÇϴ ¹æ¹ý. Àü±â¼îÅ©¿ä¹ý(electroshock therapy)À̶ó°íµµ ÇÑ´Ù. 1938³â¿¡ ÀÌÅ»¸®¾ÆÀǠü¸¦·¹Æ¼¿Í ºñ´Ï¿¡ ÀÇÇØ ½ÃÀ۵Ǿú´Ù. ÀÛ¿ë±âÀüÀº È®½ÇÄ¡ ¾ÊÀ¸³ª ³úÀÇ ½ÅÁø´ë»ç, »ýÈ­ÇР¹× È¿¼Ò µî¿¡ º¯È­¸¦ ÀÏÀ¸Å²´Ù´Â »ý¹°ÇÐÀû, »ýÈ­ÇÐÀû Çм³ÀÌ À¯·ÂÇÏ´Ù.
  
  ÀûÀÀÁõÀ¸·Î °¡Àå È¿°úÀûÀΠº´Àº ¿ì¿ïÁõÀ¸·Î Æ¯È÷ ¿©¼º¿¡¼­ °»³â±â¿¡ È£¹ßÇϴ °»³â±â ¿ì¿ïÁõ, ¿ì¿ïÁõ°ú Á¶Áõ(¾ÆÁÖ ±âºÐÀÌ ÁÁÀº »óŰ¡ Áö¼ÓµÇ´Â Á¤½Åº´)ÀÌ ÀÏÁ¤ÇÑ Áֱ⸦ µÎ°í ¹Ýº¹Çϴ Á¶¿ïÁõ¿¡ Àß ¾²À̸ç, 80~90%¿¡¼­ È¿°ú°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • radiation therapy
    ¹æ»ç¼±Ä¡·á, ¹æ»ç¼±¿ä¹ý
  • replacement therapy
    ´ëÄ¡¿ä¹ý
  • speech therapy
    ¾ð¾îÄ¡·á
  • supportive therapy
    ÁöÁö¿ä¹ý
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • systemic therapy
    Àü½Å¿ä¹ý
  • ultrasonic therapy
    ÃÊÀ½ÆÄ¿ä¹ý
  • ultrasound therapy
    ÃÊÀ½ÆÄ¿ä¹ý
  • vaccine therapy
    ¹é½Å¿ä¹ý
  • will therapy
    ÀÇÁö¿ä¹ý
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    Ç׺ҾÈÁ¦, ºÒ¾ÈÄ¡·áÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • orthodontic therapy
    ±³Á¤¿ä¹ý
  • palliative therapy
    °í½Ä¿ä¹ý
  • photodynamic therapy
    ±¤¼±¿ªÇпä¹ý
  • photoradiation therapy
    ±¤¹æ»çÄ¡·á
  • physical therapy
    ¹°¸®Ä¡·á
  • play therapy
    ³îÀÌ¿ä¹ý
  • prolonged sleep therapy
    ¼ö¸é¿¬ÀåÄ¡·á
  • psychobiological therapy
    Á¤½Å»ý¹°ÇÐÀû¿ä¹ý
  • psychosocial therapy
    Á¤½Å»çȸ¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±¿ä¹ý
  • radioactive isotope therapy unit
    ¹æ»ç¼ºµ¿À§¿ø¼ÒÄ¡·á±â
  • rational-emotive therapy
    À̼º°¨¼º¿ä¹ý
  • reality therapy
    Çö½Ç¿ä¹ý
  • replacement therapy
    º¸»ó¿ä¹ý
  • self-control therapy
    ÀÚ±âÁ¶Àý¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • prescription drug
    󹿾à.
  • pressor drug
    Ç÷¾Ð»ó½ÂÁ¦.
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅȰ¼º ¾à¹°(?)
  • psychoactive drug
    Á¤½ÅȰ¼ºÁ¦
  • Chelation therapy
    ų·¹ÀÌÆ® ¿ä¹ý
  • ECT=Electroconvulsive Therapy
    Àü±â°æ·Ã¿ä¹ý
  • EST See Electroshock therapy
    Àü±âÃæ°Ý¿ä¹ý(ï³Ñ¨õú̪èþÛö)
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • RePUVA therapy
    ·¹Æ¼³ëÀ̵å+PUVA
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • acupuncture therapy
    ħ¼ú¿ä¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • bioreductive drug
    »ýüȯ¿ø¼º¾àÁ¦, -¾à¹°
  • bullous drug eruption
    ¼öÆ÷¼º ¾àÁø(¡­å·òÖ)
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • cardiotropic drug
    ½ÉÀåģȭ¼º ¾àÁ¦
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug(=enhancer)
    ÀÎÁö±â´ÉȰ¼ºÁ¦(ìãò±Ñ¦ÒöüÀàõð¥)
  • common drug =c. medicament
    º¸Åë¾à(ÜÅ÷×å·).
  • competitive drug
    °æÇÕ¾à(Ìæùêå·).
  • crude drug
    »ý¾à(ßæå·), Á¶¾à.
  • cutaneous drug reaction
    ÇǺξàÁø
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°.
  • cytotoxic drug
    Ç÷¾×Æ÷µ¶¼ºÁ¦<¾à>, ¼¼Æ÷µ¶¼º ¾à¹°.
  • dependence, drug
    ¾àÁ¦ÀÇÁ¸¼º
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ERT esophageal radionuclide transit; estrogen replacement therapy; examination room terminal; external r...
ICT icteric, icterus; indirect Coombs test; inflammation of connective tissue; insulin coma therapy; int...
OT objective test; oblique talus; occlusion time; occupational therapist, occupational therapy; ocular ...
PT pain threshold; parathormone; parathyroid; paroxysmal tachycardia; part time; patient; pericardial t...
ADI Acute Drug Intoxication
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DEA Drug Enforcement Administration
DIC Drug Information Center
DRP Drug Related Problems
D.U.E. Drug Use Evaluation
DUR Drug Use Review
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • occlusal splint therapy
    ±³ÇÕ ÀåÄ¡ ¿ä¹ý
  • occlusal therapy
    ±³ÇÕ Ä¡·á
  • occupational therapy
    ÀÛ¾÷ ¿ä¹ý
    Ä¡·á ¸ñÀûÀ» À§ÇÑ ÀÛ¾÷ÀÇ Àû¿ë.
  • palliative therapy
    °í½ÄÀû Ä¡·á
  • prosthodontic therapy
    º¸Ã¶ Ä¡·á
  • radiation therapy
    ¹æ»ç¼± Ä¡·á
    °í¿¡³ÊÁö ¹æ»ç¼±À¸·Î ¾Ï ¼¼Æ÷¸¦ Á×À̰ųª ¼Õ»ó½ÃŰ´Â Ä¡·á¹ý. ¿ÜºÎ ¹æ»ç¼± Ä¡·á´Â °í¿¡³ÊÁö ¹æ»ç¼±À» ü¿Ü¿¡¼­ ¾Ï¿¡ Á¶ÁØÇÏ¿© ÂÉÀÌ´Â °ÍÀÌ´Ù. ³»ºÎ ¹æ»ç¼± Ä¡·á´Â ¹æ»ç¼º ¹°ÁúÀ» ü³» ¾Ï °¡±î¿î °÷¿¡ ³Ö¾î Ä¡·áÇÏ´Â °ÍÀÌ´Ù.
  • radioactive iodine therapy
    ¹æ»ç¼± Ȱ¼º ¿ä¿Àµå Ä¡·á
  • reality therapy
    Çö½Ç Ä¡·á
  • rehabilitative therapy
    ÀçÆÈ ¿ä¹ý
  • reversible occlusal therapy
    °¡¿ªÀûÀÎ ±³ÇÕ Ä¡·á, °¡¿ªÀû ±³ÇÕ Ä¡·á
  • sero therapy
    Ç÷û ¿ä¹ý
    ¼¼Æ÷ °¨¿°Áõ °¡¿îµ¥ ¿Üµ¶¼Ò¿¡ ÀÇÇØ »ý±â´Â ÁúȯÀ̳ª ¹ìÀÇ ±³ÁõÀ» Ä¡·áÇÏ´Â ¹æ¹ý Áß ÇϳªÀÌ´Ù.
  • solid carbon dioxide therapy
    °íü ź»ê °¡½º ¿ä¹ý
  • splint therapy
    ±³ÇÕ ÀåÄ¡ ¿ä¹ý
  • substitution therapy
    º¸Ãæ ¿ä¹ý
    ³»ºÐºñ¼±ÀÇ ±â´É ºÎÀüÀ» º¸ÃæÇϱâ À§ÇÑ È£¸£¸óÀÇ Åõ¿©.
  • supervoltage roentgen therapy
    Ãʰí¾Ð X¼± Ä¡·á
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
drug costs The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (fees, pharmaceutical or prescription fees).
(12 Dec 1998)
drug delivery The method and route used to provide medication.
(16 Dec 1997)
drug delivery systems Systems of administering drugs through controlled delivery so that an optimum amount reaches the target site. Drug delivery systems encompass the carrier, route, and target.
(12 Dec 1998)
drug dependence Use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed. Drug dependence is a compulsion to take a drug to produce a desired effect or prevent unpleasant effects when the drug is withheld. Risk factors for drug abuse include: low self esteem, inability to deal with stress and emotional instability. Juveniles use drugs due to peer pressure. Signs of drug use in children include: a change in friends or group, long absences from home, poor performance in school, seclusion, stealing, lying, criminal behaviour, deteriorating family relationships, signs of drug intoxication and changes in behaviour. Commonly abused drugs include narcotic analgesic agents, benzodiazepines, cocaine, amphetamines, barbiturates, marijuana, LSD and phencyclidine. Many labs now offer quick and inexpensive urine drug screening. Psychological counseling and parental support will be necessary in children with this problem.
(27 Sep 1997)
drug design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
(12 Dec 1998)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
drug eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
(12 Dec 1998)
drug evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
(12 Dec 1998)
drug-fast Pertaining to microorganisms that resist or become tolerant to an antibacterial agent.
(05 Mar 2000)
drug fever Fever resulting from an allergic reaction to a drug that clears rapidly on discontinuation of the drug.
(05 Mar 2000)
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
drug holiday Interval when a chronically medicated patient temporarily stops taking the medication; used to allow some recuperation of normal functions, to maintain sensitivity to the drug, and to reduce the likelihood of side-effects.
(05 Mar 2000)
drug hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
(12 Dec 1998)
drug implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
(12 Dec 1998)
drug incompatibility <pharmacology> The quality of not being miscible with another given substance without a chemical change.
One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á